Safeguard the Right-To-Try Cutting-Edge Medicine Act

Summary

The law defines a "right‑to‑try" process for patients with life‑threatening or severely disabling illnesses who have exhausted FDA‑approved options. Eligible patients can receive investigational drugs, biologics, or devices that have passed Phase 1 trials or are custom‑made for their genetics, provided a physician recommends them and the patient signs a comprehensive informed‑consent form. The measure excludes patients currently hospitalized and places the cost burden on the patient.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share